(thirdQuint)Treatment Preference for Weekly DPP-4 Inhibitors Versus Daily DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus.

 The drugs being tested in this study are called Trelagliptin and Alogliptin.

 This study will look at the patient preference for treatment with Trelagliptin versus Alogliptin.

 The study will enroll approximately 60 patients.

 Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups: - Trelagliptin 100 mg, followed by Alogliptin 25 mg - Alogliptin 25 mg, followed by Trelagliptin 100 mg All participants will be asked to take one tablet of Trelagliptin orally once a week or one tablet of Alogliptin orally once a day throughout the study period.

 This multi-center trial will be conducted in Japan.

 The overall time to participate in this study is 16 weeks.

 Participants will make multiple visits to the clinic.

.

 Treatment Preference for Weekly DPP-4 Inhibitors Versus Daily DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus@highlight

The purpose of this study is to examine the patient preference for treatment with once-weekly dosing of DPP-4 inhibitor trelagliptin versus once-daily dosing of DPP-4 inhibitor alogliptin among the participants with type 2 diabetes mellitus who are being treated with once-daily dosing of DPP-4 inhibitor.

